Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Katie Ryan
Medical Advisor, Haematology
The first & only JAK inhibitor indicated specifically for myelofibrosis (MF) patients with moderate to severe anaemia.¹
NOW AVAILABLE
Want to know more about OMJJARA▼ (momelotinib)?
Get in touch with your local GSK Ireland Team today to learn more.
Adverse event reporting information can be found at the bottom of this page
Summary of product characteristics & Patient information leaflet for 100 mg, 150 mg and 200 mg film coated tablets
INDICATION
OMJJARA is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Reference
- OMJJARA Summary of Product Characteristics (SPC), available on www.medicines.ie/medicines/omjjara-100-150-200-mg-film-coated-tablets-36329/spc. Last accessed: September 2024.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Omjjara is a registered trademark of the GlaxoSmithKline group of companies.
Get more from GSKpro
Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines
February 2025 | PM-IE-MML-WCNT-250001
